Cerdulatinib for treating myeloma

Abstract

Compositions and methods for treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof. The methods entail administering to the patient an effective amount of cerdulatinib.

1 . A method of treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof, comprising administering to the patient an effective amount of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the effective amount is from about 5 mg to about 150 mg daily. 
     
     
         2 . The method of  claim 1 , wherein the patient is not being treated with fludarabine. 
     
     
         3 . The method of  claim 1 , wherein the patient is not being treated with a purine analog. 
     
     
         4 . The method of  claim 1 , wherein the patient is not being treated with an agent that interferes with DNA synthesis. 
     
     
         5 . The method of  claim 1 , wherein the administration is once daily. 
     
     
         6 . The method of  claim 1 , wherein the administration is twice daily. 
     
     
         7 . The method of  claim 6 , wherein the effective amount is from about 25 mg to about 65 mg twice daily. 
     
     
         8 . The method of  claim 6 , wherein the effective amount is about 30 mg, 35 mg, 40 mg, 45 mg, or 50 mg twice daily. 
     
     
         9 . The method of  claim 1 , wherein the patient suffers from an advanced malignancy of MM, AML or MPD. 
     
     
         10 . The method of  claim 1 , wherein the patient has relapsed or not responded to a prior chemotherapy. 
     
     
         11 . The method of  claim 10 , wherein the patient has failed at least two prior therapies. 
     
     
         12 . The method of  claim 1 , wherein the multiple myeloma is a Stage I, Stage II, or Stage III multiple myeloma. 
     
     
         13 . The method of  claim 1 , wherein the patient has an albumin level lower than 3.5 mg/dL. 
     
     
         14 . The method of  claim 1 , wherein the patient has a B2-microglobulin level from 3.5 to 5 mg/L or greater than 5 mg/L. 
     
     
         15 . The method of  claim 1 , wherein the patient has an FGFR3 activation mutation. 
     
     
         16 . The method of  claim 1 , wherein the multiple myeloma is Monoclonal Gammopathy of Undetermined Significance (MGUS), Asymptomatic (Smoldering/Indolent) Myeloma, or Symptomatic (Active) Myeloma. 
     
     
         17 . The method of  claim 1 , further comprising administering to the patient a second agent. 
     
     
         18 . The method of  claim 17 , wherein the second agent is a P90RSK inhibitor. 
     
     
         19 . The method of  claim 17 , wherein the second agent is selected from the group consisting of dexamethasone, melphalan, doxorubicin, bortezomib, lenalidomide, prednisone, carmustine, etoposide, cisplatin, vincristine, cyclophosphamide, BI-D1870, and thalidomide.